Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes

Authors

  • G. Kaur,

    Corresponding author
    1. Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
      Gurvinder Kaur
      Department of Transplant Immunology and Immunogenetics
      All India Institute of Medical Sciences
      Ansari Nagar
      New Delhi 110029
      India
      Tel: +91 11 2659 3769
      Fax: +91 11 2658 8663
      e-mail: gurvinder@hotmail.com
    Search for more papers by this author
  • N. Mehra

    1. Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    Search for more papers by this author

Gurvinder Kaur
Department of Transplant Immunology and Immunogenetics
All India Institute of Medical Sciences
Ansari Nagar
New Delhi 110029
India
Tel: +91 11 2659 3769
Fax: +91 11 2658 8663
e-mail: gurvinder@hotmail.com

Abstract

Genomic studies involving well-defined multicenter cohorts of HIV-1/AIDS covering multiple populations have led to a greater understanding of the role of host determinants in viral acquisition, disease progression, transmission, and response to anti-retroviral therapy. Similarly, recent knowledge on the virus genetic diversity has helped in elucidating mechanisms leading to the evolution of viral escape mutants and the role played by host immune determinants, in particular the major histocompatibility complex (MHC) associated genes. At least two alleles, HLA-B*27 and B*57, have been identified as ‘protective’ against HIV-1 while B*35 and B*53 act as susceptibility favoring factors. How human leukocyte antigen (HLA)-mediated selection drives the evolution of HIV-1 and which circulating variants are more likely to evade immune surveillance of the population are now beginning to become clear. Importantly, the rare HLA alleles in a population bear a selective advantage to the host because these can induce immune responses against pre-adapted viruses. It is conceivable that previously established protective HLA associations are shifting with the evolving cytotoxic T lymphocyte (CTL) epitopes and may not remain protective in future. At the same time, this process is unraveling novel sub-dominant epitopes of the virus which could now be incorporated as the dominant target CTL epitopes. An insight into the population-specific correlates of protection is hence necessary for designing future anti-HIV therapeutic and/or prophylactic vaccine formulation(s).

Ancillary